Pasithea Therapeutics Corp. Quarterly report pursuant to Section 13 or 15(d)

Warrants (Details) - Schedule of outstanding warrants	3 Months Ended
Warrants (Details) - Schedule of outstanding warrants	Mar. 31, 2023 $ / shares shares
Warrants (Details) - Schedule of outstanding warrants [Line Items]
Number of warrants \| shares	15,356,000
Weighted-average remaining contractual term (years)	3 years 8 months 8 days
Weighted-average exercise price \| $ / shares	$ 4.12
1.88 [Member]
Warrants (Details) - Schedule of outstanding warrants [Line Items]
Exercise Price \| $ / shares	$ 1.88
Number of warrants \| shares	2,000,000
Weighted-average remaining contractual term (years)	4 years 4 months 17 days
3.50 [Member]
Warrants (Details) - Schedule of outstanding warrants [Line Items]
Exercise Price \| $ / shares	$ 3.5
Number of warrants \| shares	8,680,000
Weighted-average remaining contractual term (years)	3 years 7 months 24 days
6.00 [Member]
Warrants (Details) - Schedule of outstanding warrants [Line Items]
Exercise Price \| $ / shares	$ 6
Number of warrants \| shares	276,000
Weighted-average remaining contractual term (years)	3 years 5 months 19 days
6.25 [Member]
Warrants (Details) - Schedule of outstanding warrants [Line Items]
Exercise Price \| $ / shares	$ 6.25
Number of warrants \| shares	4,400,000
Weighted-average remaining contractual term (years)	3 years 5 months 19 days